Physician profile
Molly E Rorex
NPI 1629804778
$1,427.09
in general payments reported to CMS, 2019-2025
24 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $266 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $250.24 | 2025 | Nuzyra |
| Amgen INC. | $171.71 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $110.04 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $90.33 | 2024-2025 | Breztri, Farxiga |
| Exact Sciences Corporation | $84.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $77.68 | 2025 | |
| Novo Nordisk INC | $72.23 | 2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $67.48 | 2025 | Zepbound, Mounjaro |
| Corcept Therapeutics | $61.85 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.24 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.91 | 2024-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $42.32 | 2024 | |
| Ardelyx, INC. | $36.21 | 2024 | Ibsrela |
| Medtronic, INC. | $35.18 | 2025 | Minimed 780g |
| Astellas Pharma US INC | $34.37 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.72 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $26.04 | 2025 | Voquezna |
| Radius Health, INC. | $22.40 | 2024 | Tymlos |
| Merck Sharp & Dohme LLC | $22.07 | 2025 | Verquvo, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $20.03 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $19.60 | 2025 | Nexletol |
| Genentech USA, INC. | $17.21 | 2025 | Hemlibra |
| Idorsia Pharmaceuticals US INC | $17.06 | 2025 | Quviviq |
| Tolmar, INC. | $16.32 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Rorex listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.